Authors
Latest:
Characterizing Tumor Cell Diversity with AI“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Latest:
Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple MyelomaClosing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
Latest:
Redefining the Treatment Paradigm in Low Grade Serous Ovarian CancerLow grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Latest:
CAR-NKT cells: More of a Goldilocks or a Kangaroo?The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.
Latest:
Elacestrant Combos Can Open New Pathways in ESR1 Breast Cancer TreatmentMultiple targeted therapies/sequencing possibilities are available following elacestrant’s approval for patients with breast cancer, Maxwell Lloyd, MD, said.
Latest:
Unmet Needs and Future Directions in Care in Multiple MyelomaClosing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.
Latest:
Current Frontline Treatment of Multiple MyelomaSarah A. Holstein, MD, PhD, reviews updated treatment options for patients with newly diagnosed multiple myeloma.
Latest:
Immunotherapy for CNS Melanoma: RELATIVITY-020’s Intracranial Efficacy DataPanelists discuss evolving treatment strategies for metastatic melanoma with asymptomatic brain metastases, highlighting the superiority of PD-1 plus CTLA-4 combination therapy for durable intracranial responses, while noting that newer immunotherapy combinations like PD-1 plus LAG-3 show promise but require further evidence before altering current standards of care.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Adverse Event Considerations in DLBCLMedical oncologists conclude their discussion with a review of the toxicity profiles of treatments for diffuse large B-cell lymphoma.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
Non-Clear Cell RCC: Key Learnings and Future Research DirectionsThe panel discusses key learnings from recent studies in non-clear cell RCC subtypes and the need to better understand disease biology to develop optimized, histology-specific therapies rather than extrapolating clear cell treatment approaches.
Latest:
Research Considerations for ctDNA Testing in Colorectal CancerPanelists discuss how research on circulating tumor DNA (ctDNA) testing in colorectal cancer requires careful consideration of standardized collection protocols, analytical validation, clinical utility assessment, integration with existing biomarkers, and longitudinal monitoring to establish its role in personalized treatment decision-making.
Latest:
Psycho-Oncology and the Relevance of a Biopsychosocial Screening ProgramRoutine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Latest:
Unmet Needs and Looking Ahead in Follicular LymphomaSameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.
Latest:
The Future of BRAF-Mutant mCRC ManagementChristina Wu, MB, BCh, MD, closes the program by expressing the necessity of enrolling patients with BRAF-mutant metastatic colorectal cancer in clinical trials, highlighting a second-line study led by the Southwest Oncology Group, new BRAF inhibitors, early phase studies at the Mayo Clinic, and an exciting study in the adjuvant setting.
Latest:
Collaboration Brings “Excitement” to Novel Cancer Therapy DevelopmentGeraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Latest:
Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOLAuthors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.
